A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE, 2-PERIOD STUDY IN HEALTHY ADULT MALE PARTICIPANTS TO ASSESS THE EXTENT OF EXCRETION, ABSOLUTE BIOAVAILABILITY, FRACTION ABSORBED, AND PHARMACOKINETICS OF [14C]PF-06865571 USING A 14C-MICROTRACER APPROACH
Latest Information Update: 02 Aug 2024
At a glance
- Drugs Ervogastat (Primary) ; Ervogastat (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 07 Oct 2021 Status changed from recruiting to completed.
- 01 Jul 2021 Status changed from not yet recruiting to recruiting.
- 06 May 2021 New trial record